Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy

Sustained therapeutic responses from traditional and next-generation antiandrogen therapies remain elusive in clinical practice due to inherent and/or acquired resistance resulting in persistent androgen receptor (AR) activity. Antisense oligonucleotides (ASO) have the ability to block target gene e...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Autores principales: De Velasco, Marco A., Kura, Yurie, Sakai, Kazuko, Hatanaka, Yuji, Davies, Barry R., Campbell, Hayley, Klein, Stephanie, Kim, Youngsoo, MacLeod, A. Robert, Sugimoto, Koichi, Yoshikawa, Kazuhiro, Nishio, Kazuto, Uemura, Hirotsugu
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2019
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777919/
https://ncbi.nlm.nih.gov/pubmed/31484823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.122688
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares